Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Vericel Corproation (VCEL)

Vericel Corproation (VCEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,126,268
  • Shares Outstanding, K 47,223
  • Annual Sales, $ 156,180 K
  • Annual Income, $ -7,470 K
  • 60-Month Beta 1.93
  • Price/Sales 6.97
  • Price/Cash Flow N/A
  • Price/Book 6.11
Trade VCEL with:

Options Overview Details

View History
  • Implied Volatility 65.49% ( +11.59%)
  • Historical Volatility 115.82%
  • IV Percentile 50%
  • IV Rank 36.66%
  • IV High 89.43% on 09/21/22
  • IV Low 51.63% on 10/05/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 41
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 770
  • Open Int (30-Day) 586

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 0.02
  • Number of Estimates 2
  • High Estimate 0.05
  • Low Estimate -0.01
  • Prior Year 0.09
  • Growth Rate Est. (year over year) -77.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.30 +31.21%
on 11/09/22
25.09 -9.53%
on 11/07/22
-2.26 (-9.05%)
since 11/04/22
3-Month
17.30 +31.21%
on 11/09/22
27.87 -18.55%
on 11/02/22
+0.01 (+0.04%)
since 09/02/22
52-Week
17.30 +31.21%
on 11/09/22
43.97 -48.37%
on 03/03/22
-12.96 (-36.34%)
since 12/03/21

Most Recent Stories

More News
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

VCEL : 22.70 (-4.82%)
OCEL : 0.0280 (-12.50%)
BRTX : 3.48 (-5.33%)
MDXG : 3.13 (-7.94%)
NNVC : 1.6400 (-2.96%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...

OCEL : 0.0280 (-12.50%)
BRTX : 3.48 (-5.33%)
MDXG : 3.13 (-7.94%)
NNVC : 1.6400 (-2.96%)
VCEL : 22.70 (-4.82%)
Vericel Corporation (VCEL) Reports Q3 Loss, Lags Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 3.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

VCEL : 22.70 (-4.82%)
IMTX : 11.13 (-1.15%)
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 23.40% and 44.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ZYME : 7.62 (+0.53%)
VCEL : 22.70 (-4.82%)
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 25.93% and 24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CRDF : 1.5600 (-0.64%)
VCEL : 22.70 (-4.82%)
How Much Upside is Left in Vericel Corporation (VCEL)? Wall Street Analysts Think 53%

The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Vericel Corporation (VCEL). While the effectiveness of this highly sought-after metric is questionable,...

VCEL : 22.70 (-4.82%)
Vericel (VCEL) Q2 2022 Earnings Call Transcript

VCEL earnings call for the period ending June 30, 2022.

VCEL : 22.70 (-4.82%)
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -46.15% and 3.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VCEL : 22.70 (-4.82%)
KYMR : 29.11 (-5.43%)
Vericel Reports Second Quarter 2022 Financial Results

Second Quarter Total Net Revenue of $37.0 Million MACI Net Revenue of $28.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE,...

VCEL : 22.70 (-4.82%)
Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel

Data published in the Journal of Burn Care & Research show 83% of patients with posterior burns (mean total body surface area of 56%) had successful...

VCEL : 22.70 (-4.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

3rd Resistance Point 24.71
2nd Resistance Point 24.13
1st Resistance Point 23.41
Last Price 22.70
1st Support Level 22.11
2nd Support Level 21.53
3rd Support Level 20.81

See More

52-Week High 43.97
Fibonacci 61.8% 33.78
Fibonacci 50% 30.63
Fibonacci 38.2% 27.49
Last Price 22.70
52-Week Low 17.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar